Alnylam Pharmaceuticals (ALNY) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Genmab A/S (GMAB) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 16.4% versus a loss of 49.1%. Over five years, ALNY leads with a +11.6% price change compared with -18.9% for GMAB. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $22.79 billion), about 1.4 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (18.7x vs 24.3x for Genmab A/S). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | GMAB |
|---|---|---|
| Share price | $232.68 | $37.07 |
| Market cap | $31.13B | $22.79B |
| 1-day change | +3.63% | +2.83% |
| YTD return | -41.49% | +20.36% |
| 1-year return | -49.08% | +16.39% |
| 5-year return | +11.57% | -18.86% |
| P/E ratio (TTM) | 39.24 | 28.52 |
| Forward P/E | 18.73 | 24.31 |
| EPS (TTM) | $5.93 | $1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $3.72B |
| Revenue growth (YoY) | +65.19% | +19.19% |
| Net income (latest FY) | $313.75M | $963.00M |
| Gross margin | 81.77% | 93.60% |
| Operating margin | 13.51% | 28.63% |
| Net margin | 8.45% | 25.89% |
| 52-week high | $495.55 | $40.17 |
| 52-week low | $197.81 | $23.62 |
| Distance from 52-week high | -53.05% | -7.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +59.50% | +16.59% |
| Average volume | 1.75M | 2.79M |
| Shares outstanding | 133.81M | 614.90M |
| Employees | 2,500 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMAB has outperformed ALNY by 65.5 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (39.2x vs 28.5x trailing P/E).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +19.19%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
ALNY vs GMAB FAQ
Which is bigger, Alnylam Pharmaceuticals or Genmab A/S?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $22.79B for Genmab A/S (GMAB).
Which stock has performed better over the past year, ALNY or GMAB?
GMAB returned +16.39% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or GMAB?
GMAB has the lower trailing P/E at 28.5, versus 39.2 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and Genmab A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.